Corporate-backed medical imaging technology producer Lunit is preparing to float in South Korea while cancer drug developer Pheast secured $76m from investors including Alexandria Venture Investments.

Funding

Alexandria Venture Investments, the venture capital arm of real estate investment trust Alexandria Real Estate Equities, took part in a $76m series A round yesterday for Pheast Therapeutics, a US-based cancer drug developer spun out of Stanford University. Catalio Capital Management and Arch Venture Partners co-led the round, which also featured Risk and Reward and, according to MedCity News, Stanford University’s Presidential Venture Fund.

US-headquartered token exchange technology developer 0x Labs secured $70m in series B funding yesterday from…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn